See more : JOHN COCKERILL INDIA LIMITED (COCKERILL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of MGC Pharmaceuticals Limited (MGCLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MGC Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hagerty, Inc. (HGTY) Income Statement Analysis – Financial Results
- Wealthking Investments Limited (1140.HK) Income Statement Analysis – Financial Results
- West Cobar Metals Limited (WC1.AX) Income Statement Analysis – Financial Results
- GSR II Meteora Acquisition Corp. (GSRMR) Income Statement Analysis – Financial Results
- Silver Lake Resources Limited (SLR.AX) Income Statement Analysis – Financial Results
MGC Pharmaceuticals Limited (MGCLF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://mgcpharma.com.au
About MGC Pharmaceuticals Limited
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.39M | 4.65M | 2.96M | 2.03M | 656.24K | 296.81K | 120.24K | 2.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Cost of Revenue | 1.94M | 3.01M | 1.65M | 1.90M | 356.64K | 119.34K | 158.07K | 15.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.45M | 1.63M | 1.31M | 130.15K | 299.60K | 177.47K | -37.83K | -12.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Gross Profit Ratio | 42.82% | 35.15% | 44.23% | 6.40% | 45.65% | 59.79% | -31.46% | -583.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.99M | 4.24M | 5.86M | 5.37M | 2.87M | 951.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.13M | 8.28M | 5.73M | 6.61M | 2.61M | 3.36M | 4.27M | 683.09K | 510.09K | 244.11K | 362.77K | 101.01K | 98.33K | 1.43M | 1.70M | 1.39M | 1.03M | 0.00 |
| Selling & Marketing | 926.91K | 949.83K | 583.19K | 562.13K | 574.98K | 612.76K | 204.76K | 240.26K | 36.39K | 12.33K | 9.38K | 3.16K | 4.83K | 223.63K | 326.02K | 477.93K | 462.40K | 0.00 |
| SG&A | 13.06M | 9.23M | 6.31M | 6.61M | 3.19M | 3.97M | 4.47M | 923.35K | 546.48K | 256.43K | 372.16K | 104.17K | 103.17K | 1.65M | 2.03M | 1.86M | 1.49M | 0.00 |
| Other Expenses | -578.77K | -1.18M | -425.12K | 524.32K | 9.46M | -1.79M | -1.29M | -1.78M | -6.51K | 1.60K | -27.35K | 15.00K | 28.39K | 951.09K | 155.02K | 27.97K | 2.59M | 0.00 |
| Operating Expenses | 17.05M | 15.08M | 13.38M | 12.55M | 9.34M | 7.44M | 7.28M | 4.36M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Cost & Expenses | 24.26M | 18.10M | 15.03M | 14.45M | 9.70M | 7.56M | 7.44M | 4.38M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Interest Income | 240.00 | 300.00 | 7.63K | 12.34K | 201.85K | 191.59K | 127.26K | 46.03K | 5.89K | 7.10K | 25.66K | 38.06K | 7.12K | 759.08K | 390.37K | 27.97K | 40.94K | 0.00 |
| Interest Expense | 257.40K | 190.05K | 369.14K | 135.58K | 8.00K | 99.37K | 19.72K | 120.01K | 0.00 | 0.00 | 0.00 | 0.00 | 95.14K | 1.74M | 573.54K | 11.34K | 25.89K | 0.00 |
| Depreciation & Amortization | 751.94K | 504.30K | 491.41K | 481.13K | 259.74K | 328.11K | 83.52K | 16.58K | 0.00 | 0.00 | 8.33K | 0.00 | 0.00 | 166.64K | 35.47K | 47.60K | 40.48K | 0.00 |
| EBITDA | -14.69M | -15.16M | -12.00M | -13.04M | -8.45M | -8.54M | -8.40M | -6.09M | -3.80M | -5.35M | -756.87K | -343.94K | -216.95K | -855.93K | -1.34M | -1.57M | -55.88K | 0.00 |
| EBITDA Ratio | -455.34% | -303.90% | -404.87% | -443.15% | 134.22% | -2,875.65% | -6,984.90% | -277,354.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -243.40% | -63.32% | -82.21% | -2.13% | 0.00% |
| Operating Income | -15.23M | -14.63M | -12.49M | -9.50M | 621.07K | -8.86M | -8.48M | -6.11M | -3.80M | -5.35M | -765.21K | -343.94K | -216.95K | -1.02M | -1.37M | -1.61M | -96.37K | 0.00 |
| Operating Income Ratio | -449.72% | -314.75% | -421.46% | -466.80% | 94.64% | -2,986.19% | -7,054.36% | -278,109.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -290.78% | -65.00% | -84.70% | -3.67% | 0.00% |
| Total Other Income/Expenses | -5.90M | -1.64M | -1.59M | -7.48M | 6.84M | -1.94M | -1.21M | -2.01M | -166.94K | -2.65K | -27.35K | 53.06K | -232.49K | -2.16M | -573.54K | -11.34K | 14.60K | 0.00 |
| Income Before Tax | -21.13M | -17.14M | -13.53M | -18.81M | -1.88M | -8.99M | -8.50M | -6.23M | -3.80M | -5.34M | -766.90K | -290.88K | -449.44K | -3.18M | -1.95M | -1.63M | -81.77K | 0.00 |
| Income Before Tax Ratio | -623.80% | -368.81% | -456.71% | -924.70% | -285.93% | -3,029.02% | -7,070.76% | -283,571.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -904.30% | -92.17% | -85.30% | -3.11% | 0.00% |
| Income Tax Expense | 2.02K | -1.36M | -27.28K | 1.21M | 27.32K | -1.04K | -1.63M | -1.73M | 0.00 | 0.00 | -25.66K | 0.00 | -117.28K | 2.14M | 728.55K | 251.84K | 2.57M | 0.00 |
| Net Income | -20.82M | -16.77M | -13.97M | -19.36M | -2.31M | -8.25M | -8.14M | -6.16M | -3.80M | -5.34M | -766.90K | -290.88K | 1.94M | -2.63M | -1.95M | -1.88M | -81.77K | 0.00 |
| Net Income Ratio | -614.71% | -360.79% | -471.33% | -951.67% | -351.91% | -2,778.31% | -6,773.31% | -280,252.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -748.06% | -92.17% | -98.51% | -3.11% | 0.00% |
| EPS | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.40 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| EPS Diluted | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.37 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| Weighted Avg Shares Out | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.81K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
| Weighted Avg Shares Out (Dil) | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.96K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
MGC Pharmaceuticals applies for cannabinoid brain disorder patent
MGC Pharmaceuticals Limited (LON:MXC) has submitted a patent application in Europe for a cannabinoid drug delivery formulation that can increases doses to the brain. The initial application for the self-nano emulsifying cannabinoids-ionic complex concentrate drug delivery system (SNEDDS) has been submitted...
MGC Pharmaceuticals gets phase III trial of lead drug underway
MGC Pharmaceuticals Ltd (ASX:MXC, LON:MXC) hailed as a “major milestone” the recruitment of its first patient to a phase III trial of its cannabis-derived drug in patients hospitalised with Covid. In all, 252 people will take part in the double-blind,...
MGC Pharmaceuticals epilepsy product added to Primary Care Reimbursement Service making it free of charge for Irish patients
MGC Pharmaceuticals Ltd's (ASX:MXC) (LSE:MXC) (OTCMKTS:MGCLF) cannabis-derived epilepsy product CannEpil® has been added to the Primary Care Reimbursement Service (PCRS) in Ireland which makes it free of charge for patients prescribed the treatment. The investigational medicinal product is already part of Ireland's Medicinal...
MGC Pharmaceuticals appoints David Lim as joint company secretary
MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) has appointed David Lim as joint company secretary with immediate effect. Lim is a finance and corporate governance professional with more than 15 years of experience working for ASX listed companies.
MGC Pharmaceuticals progresses clinical trial planning for CimetrA, CannEpil and CogniCann
MGC Pharmaceuticals Ltd's (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) major clinical trial programs planned for CimetrA™, CannEpil® and CogniCann® in 2021 are actively progressing across Australia, Israel and Brazil. Commencement of the CimetrA Phase III to treat COVID-19 and CannEpil Phase IIb trials for treatment-resistant epilepsy...
MGC Pharmaceuticals progresses clinical trial planning for CimetrA, CannEpil and CogniCann
MGC Pharmaceuticals Ltd's (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) major clinical trial programs planned for CimetrA™, CannEpil® and CogniCann® in 2021 are actively progressing across Australia, Israel and Brazil. Commencement of the CimetrA Phase III to treat COVID-19 and CannEpil Phase IIb trials for treatment-resistant epilepsy...
MGC Pharmaceuticals submits patent application for CimetrA to European IP Office
MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) has submitted a patent application for CimetrATM, the Investigational Medicinal Product (IMP) assigned to the company, to the Slovenian Intellectual Property Office (SIPO). The company submitted its patent application that was accepted by SIPO on May 5,...
MGC Pharmaceuticals submits patent application for virus treatment
MGC Pharmaceuticals Ltd (LON:MXC) (ASX:MXC) said it has submitted a patent application for its CimetrA medical product to the Slovenian Intellectual Property Office (SIPO). CimetrA is designed to treat multiple ailments including acute and chronic inflammation, COVID-19 and variants of...
MGC Pharmaceuticals submits patent application for CimetrA to European IP Office
MGC Pharmaceuticals Ltd (LON:MXC) (ASX:MXC) said it has submitted a patent application for its CimetrA medical product to the Slovenian Intellectual Property Office (SIPO). CimetrA is designed to treat multiple ailments including acute and chronic inflammation, COVID-19 and variants of...
MGC Pharmaceuticals shares boosted by latest ArtemiC results in Covid-19 study
MGC Pharmaceuticals Ltd (LON:MXC, ASX:MXC) has announced the results of a Phase II clinical and preclinical studies on ArtemiC and its use in relation to COVID-19. The company noted that the studies evaluated the efficacy of ArtemiC on anti-inflammatory agents...
Source: https://incomestatements.info
Category: Stock Reports